Parving HH - Search Results

1

Plasma connective tissue growth factor is an independent predictor of end-stage renal disease and mortality in type 1 diabetic nephropathy.

Nguyen TQ, Tarnow L, Jorsal A, Oliver N, Roestenberg P, Ito Y, Parving HH, Rossing P, van Nieuwenhoven FA, Goldschmeding R. Nguyen TQ, et al. Among authors: parving hh. Diabetes Care. 2008 Jun;31(6):1177-82. doi: 10.2337/dc07-2469. Epub 2008 Mar 14. Diabetes Care. 2008. PMID: 18344285

2

Effects of nisoldipine and lisinopril on microvascular dysfunction in hypertensive Type I diabetes patients with nephropathy.

Sørensen VB, Rossing P, Tarnow L, Parving H, Nørgaard T, Kastrup J. Sørensen VB, et al. Clin Sci (Lond). 1998 Dec;95(6):709-17. doi: 10.1042/cs0950709. Clin Sci (Lond). 1998. PMID: 9831696 Clinical Trial.

3

Dual blockade of the renin-angiotensin system in diabetic nephropathy: a randomized double-blind crossover study.

Rossing K, Christensen PK, Jensen BR, Parving HH. Rossing K, et al. Among authors: parving hh. Diabetes Care. 2002 Jan;25(1):95-100. doi: 10.2337/diacare.25.1.95. Diabetes Care. 2002. PMID: 11772908 Clinical Trial.

4

Increased urinary albumin excretion, endothelial dysfunction, and chronic low-grade inflammation in type 2 diabetes: progressive, interrelated, and independently associated with risk of death.

Stehouwer CD, Gall MA, Twisk JW, Knudsen E, Emeis JJ, Parving HH. Stehouwer CD, et al. Among authors: parving hh. Diabetes. 2002 Apr;51(4):1157-65. doi: 10.2337/diabetes.51.4.1157. Diabetes. 2002. PMID: 11916939

5

Risk factors for development of incipient and overt diabetic nephropathy in type 1 diabetic patients: a 10-year prospective observational study.

Rossing P, Hougaard P, Parving HH. Rossing P, et al. Among authors: parving hh. Diabetes Care. 2002 May;25(5):859-64. doi: 10.2337/diacare.25.5.859. Diabetes Care. 2002. PMID: 11978681

6

Renoprotective effects of losartan in diabetic nephropathy: interaction with ACE insertion/deletion genotype?

Andersen S, Tarnow L, Cambien F, Rossing P, Juhl TR, Deinum J, Parving HH. Andersen S, et al. Among authors: parving hh. Kidney Int. 2002 Jul;62(1):192-8. doi: 10.1046/j.1523-1755.2002.00410.x. Kidney Int. 2002. PMID: 12081578 Free article. Clinical Trial.

7

PC-1 amino acid variant (K121Q) has no impact on progression of diabetic nephropathy in type 1 diabetic patients.

Jacobsen P, Grarup N, Tarnow L, Parving HH, Pedersen O. Jacobsen P, et al. Among authors: parving hh. Nephrol Dial Transplant. 2002 Aug;17(8):1408-12. doi: 10.1093/ndt/17.8.1408. Nephrol Dial Transplant. 2002. PMID: 12147787

8

Optimal dose of losartan for renoprotection in diabetic nephropathy.

Andersen S, Rossing P, Juhl TR, Deinum J, Parving HH. Andersen S, et al. Among authors: parving hh. Nephrol Dial Transplant. 2002 Aug;17(8):1413-8. doi: 10.1093/ndt/17.8.1413. Nephrol Dial Transplant. 2002. PMID: 12147788

9

Optimal dose of candesartan for renoprotection in type 2 diabetic patients with nephropathy: a double-blind randomized cross-over study.

Rossing K, Christensen PK, Hansen BV, Carstensen B, Parving HH. Rossing K, et al. Among authors: parving hh. Diabetes Care. 2003 Jan;26(1):150-5. doi: 10.2337/diacare.26.1.150. Diabetes Care. 2003. PMID: 12502672 Clinical Trial.

10

Time course of the antiproteinuric and antihypertensive effect of losartan in diabetic nephropathy.

Andersen S, Jacobsen P, Tarnow L, Rossing P, Juhl TR, Parving HH. Andersen S, et al. Among authors: parving hh. Nephrol Dial Transplant. 2003 Feb;18(2):293-7. doi: 10.1093/ndt/18.2.293. Nephrol Dial Transplant. 2003. PMID: 12543883

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

669 results

Search Page

Filters